Solid Biosciences LLC is a biotechnology business based in the US. Solid Biosciences LLC shares (SLDB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.55 – a decrease of 5.56% over the previous week. Solid Biosciences LLC employs 100 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.55 |
|---|---|
| 52-week range | $2.45 - $10.99 |
| 50-day moving average | $4.34 |
| 200-day moving average | $5.80 |
| Wall St. target price | $16.70 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.06 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.55 from 2025-04-17
| 1 week (2025-04-11) | -5.56% |
|---|---|
| 1 month (2025-03-21) | -44.57% |
| 3 months (2025-01-21) | -21.78% |
| 6 months (2024-10-21) | -56.19% |
| 1 year (2024-04-19) | -70.69% |
|---|---|
| 2 years (2023-04-20) | -48.38% |
| 3 years (2022-04-20) | 13.95 |
| 5 years (2020-04-20) | 37.275 |
| Gross profit TTM | $-96,431,000 |
|---|---|
| Return on assets TTM | -45.86% |
| Return on equity TTM | -94.57% |
| Profit margin | 0% |
| Book value | $3.39 |
| Market Capitalization | $197.6 million |
TTM: trailing 12 months
We're not expecting Solid Biosciences LLC to pay a dividend over the next 12 months.
Solid Biosciences LLC's shares were split on a 1:15 basis on 27 October 2022 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Solid Biosciences LLC shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Solid Biosciences LLC shares which in turn could have impacted Solid Biosciences LLC's share price.
Over the last 12 months, Solid Biosciences LLC's shares have ranged in value from as little as $2.45 up to $10.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Solid Biosciences LLC's is 2.07. This would suggest that Solid Biosciences LLC's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. ; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.